hemonc

Hematological predictors of thrombotic risk or disease progression in essential thrombocythemia

1:05

The evolving role of alloSCT in treatment of lymphoma

1:12

The impact of emicizumab on the hemophilia treatment landscape

1:27

Trials of interest in the mantle cell lymphoma space at ASH 2023

5:06

Advancements in AML: an update from ASH 2023

2:41

Immunotherapeutic approaches for MCL patients who progress following BTKi treatment

00:57

Mutant hematopoietic progenitor cells in MM associated with secondary primary malignancies

2:34

Inflammatory biomarkers as predictors of CAR-T efficacy in MM

2:35

Enhancing clinical care in LR-MDS: managing symptomatic/transfusion-dependent anemia

1:57

CD-7 targeted CAR-T therapy in heavily pretreated patients with AML: a Phase I trial

3:16

Hematological response to frontline treatment in LR-MDS is associated with better OS

2:08

Long-term complications in patients with hematological malignancies post-SCT

00:52

The BPDCN multi-center collaboration and global registry program

2:42

PB-04 in beta thalassemia intermedia and SCD

1:19

Advancing MCL treatment: combination therapies and updates from SYMPATICO

2:38

First-in-human trial of NX-2127 in patients with R/R B-cell malignancies

2:30

The evolving role of transplantation in multiple myeloma in the age of novel immunotherapeutics

2:03

Addition of inotuzumab to alloSCT conditioning regimen in relapsed CD22 (+) lymphoid malignancies

2:19

Acalabrutinib plus rituximab for treating anti-MAG mediated IgM peripheral neuropathy in WM

2:27

Outcomes of SCT in T-ALL and T-LBL

8:57

Targeting complement to treat PNH and other hematologic diseases

1:51

SCD highlights at ASH 2023: disease pathogenesis, ongoing clinical trials & novel gene therapies

10:30

Optimal sequencing of immunotherapies to improve outcomes for patients with multiple myeloma

1:42

UM171 improves outcomes of cord-blood transplants in high-risk leukemia

1:18

Real-world outcomes of teclistamab for R/R multiple myeloma

1:43

Current and emerging treatments for MF: an update from ASH 2023

2:55

$The challenge of treating HMA-refractory MDS patients$

1:04

The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma

1:16

Canakinumab in preventing progression of high-risk CCUS to myeloid neoplasms: a Phase II study

1:10

Long-term outcomes from key clinical trials presented at ASH 2023

3:20

ViPOR: a multi-targeted therapy for the treatment of R/R DLBCL

2:15

Clinical and prognostic implications of WT1 mutations in de novo and R/R AML

2:47

BTK inhibitors in the treatment of DLBCL: trials investigating these agents

2:48

Predictors of achieving undetectable BCR::ABL1 in patients with ALL

2:09

High-dose chemotherapy and autoSCT for R/R primary mediastinal large B-cell lymphoma

2:10

Zanubrutinib in patients with B-cell malignancies who are acalabrutinib-intolerant

1:06

Outcomes for MM patients who are TCE and BCMA-exposed are poor

1:45

Subcutaneous alnuctamab in patients with R/R multiple myeloma: the results of a Phase I trial

2:46

Exciting developments in the field of BPDCN

1:29

Unmet needs in LR-MDS: RBC transfusion-dependence

2:21

MDM2 inhibitors in myelofibrosis treatment: the addition of navtemadlin to ruxolitinib

1:30

Retrospective analysis of clinical outcomes in pts with LBCL receiving CAR-T or autoSCT while in CR

3:09

The future of CLL therapy

1:04

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3-mutated AML

1:20

Recent FDA approval of exa-cel & lovo-cel for patients with SCD

1:25

$Clinical outcomes of BTKi + ven treatment in CLL/SLL: double-exposed vs double-refractory patients$

1:53

Update on parsaclisib in patients with R/R FL treated in the CITADEL-203 trial

1:09

Improving outcomes for hemophilia patients through the implementation of gene therapies

1:11

Top NBME Concepts - Hematology (USMLE Step 1)

1:20:26

What to Expect at Your First Infusion Appointment

5:28

The use of BTK inhibitors in R/R and treatment-naïve patients with WM

1:51

The novel ICAHT grading system to predict toxicity following CAR T-cell therapy

2:48

The addition of immunotherapy to the front-line treatment of AS Hodgkin lymphoma

1:43

NVG-111, a ROR1 targeting bispecific TCE, in R/R CLL and MCL: a proof of concept Phase I study

1:29

Brexu-cel in the treatment of R/R MCL: insights from the ZUMA-2 and ZUMA-18 trials

1:54

Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure

1:58

Golcadomide, a novel CELMoD agent, with R-CHOP in patients with untreated a-BCL

1:48

Pirtobrutinib in R/R MZL: insights from the BRUIN trial

1:06

Outcomes of Ven-based regimens in CLL/SLL following intolerance or progression on covalent BTKi's

2:26

Chadi Nabhan, MD, MBA, FACP, Discusses Highlights from The HemOnc Pulse at ASCO

2:21